Condition: Chemotherapy-Induced Febrile Neutropenia · Sponsor: Qilu Pharmaceutical Co., Ltd.
The goal of this real-world study is to compare the efficacy and safety of QL0605 administered 24 hours and 48 hours after chemotherapy in breast cancer patients.
This description comes directly from the study's public registry record.
Mengli Zhu, Master · 13256715221 · mengli.zhu@qilu-pharma.com
Wangwang Zhi, Master · 17761716313 · wangwang.zhi@qilu-pharma.com
Always discuss trial participation with your own doctor first.
| Shandong Cancer Hospital | Jinan, Shandong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06616571